Report of Foreign Issuer (6-k)
May 07 2018 - 6:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 4, 2018
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S - Share repurchase programme
Bagsværd,
Denmark, 4 May 2018
- As part of the up to DKK 14 billion 2018 share repurchase programme,
Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of
up to DKK 2.7 billion in accordance with Article 5 of Regulation No 596/2014 of the European
Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour Rules.
For
that purpose, Novo Nordisk A/S has appointed Nordea Danmark, filial af Nordea Bank AB
(publ) as lead manager to execute the programme independently and without influence from
Novo Nordisk A/S. The purpose of the programme is to reduce the company's share capital
and to meet obligations arising from share-based incentive programmes. Under the agreement,
Nordea Danmark, filial af Nordea Bank AB (publ) will repurchase B shares on behalf of
Novo Nordisk A/S during the trading period starting 7 May and ending on 6 August 2018.
A maximum of 531,624 B shares can be bought during one single trading day, equal to 20%
of the average daily trading volume of Novo Nordisk B shares on Nasdaq Copenhagen during
the month of April 2018, and a maximum of 32,960,688 B shares in total can be bought
during the trading period. At least once every seven trading days, Novo Nordisk A/S will
issue an announcement in respect of the transactions made under the repurchase programme.
Page
2 of 2
Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in
diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia,
growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people
in 79 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn,
YouTube.
Further
information
Media:
|
|
|
Anne
Margrethe Hauge
|
+45
4442 3450
|
amhg@novonordisk.com
|
Ken
Inchausti (US)
|
+1
609 786 8316
|
kiau@novonordisk.com
|
|
|
|
Investors
:
|
|
|
Peter
Hugreffe Ankersen
|
+45
3075 9085
|
phak@novonordisk.com
|
Anders
Mikkelsen
|
+45
3079 4461
|
armk@novonordisk.com
|
Christina
Kjær
|
+45
3079 3009
|
cnje@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 40 / 2018
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 4, 2018
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024